AGO

Arbeitsgemeinschaft Gynäkologische Onkologie

AOCTG

Advanced Ovarian Cancer Trialists Group

ASCO

American Society of Clinical Oncology

CR

Complete Response

DFS

Disease Free Survival

DKG

Deutsche Krebsgesellschaft

DLT

Dosislimitierende Toxizitäten

FDA

Food Drug Adminsitration

CAP

Cyclophosphamid, Adriamycin, Cisplatin

CASA

Cancer Associated Serum Antigen

CTC

Common Toxicity Criteria

EORTC

European Organisation for Research and Treatment of Cancer

FIGO

Fédération Internationale de Gynécologie et d´Obstétrique

GCIG

Gynaecological Cancer Intergroup

GINECO

Groupe Investigation Nationale Etude Cancer Ovaire

GCP

Good Clinical Practice

GOG

Gynecologic Oncology Group

hMG

human Menopausal Gonadotrophin

HR

Hazard Ratio

ICON

International Collaborative Ovarian Neoplasm Group

IMO

Intraoperatives Mapping des Ovarialkarzinoms

ITT

Intention To Treat- Analysis

MITO

Multicenter Italian Trials in Ovarian Cancer

MTD

Maximal tolerable Dosis

NC

No Change

NED

No Evidence of Disease

NOGGO

Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie

NSGO

Nordic Society Gynecological Oncology

OCA

Ovarialkarzinom assoziiertes Antigen

OAS

Overall Survival

PCR

Polymerase Chain Reaction

PFS

Progression Free Survival

RFS

Recurrence Free Survival

PR

Partial Response

SD

Stable Disease

SCOTROC

Scottish Gynaecological Cancer Trials Group

SWOG

Southwest Oncology Group

TTP

Time to Progression

UKT

Unkonventionelle Krebstherapien

VEGF

Vascular Endothelial Growth Factor

WHO

World Health Organization